美国食品药品监督管理局就将KRAS状态与药物反应联系起来的事后数据举行听证会。 - Suppr

Suppr

超能文献

FDA holds court on post hoc data linking KRAS status to drug response.

作者信息

Mack George S

出版信息

Nat Biotechnol. 2009 Feb;27(2):110-2. doi: 10.1038/nbt0209-110c.

DOI:10.1038/nbt0209-110c

PMID:19204679

Abstract

摘要

相似文献

FDA holds court on post hoc data linking KRAS status to drug response.

Nat Biotechnol. 2009 Feb;27(2):110-2. doi: 10.1038/nbt0209-110c.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?

J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-2. doi: 10.1200/JCO.2008.16.8195.

[Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology].

Pathologe. 2008 Feb;29(1):93-6. doi: 10.1007/s00292-007-0966-y.

Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.

Am J Ther. 2012 Nov;19(6):395-6. doi: 10.1097/MJT.0b013e31826a94d8.

KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.

Cancer J. 2009 Mar-Apr;15(2):110-3. doi: 10.1097/PPO.0b013e31819e3202.

To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.

Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9.

KRAS status predicts response to cetuximab for metastatic colorectal cancer.

ONS Connect. 2008 Aug;23(8):25.

Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.

Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62.

Challenges and opportunities for use of cost-effectiveness analysis.

J Natl Cancer Inst. 2009 Sep 2;101(17):1161-3. doi: 10.1093/jnci/djp258. Epub 2009 Aug 7.

引用本文的文献

Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project.

Contemp Clin Trials Commun. 2017 Oct 13;8:167-174. doi: 10.1016/j.conctc.2017.10.003. eCollection 2017 Dec.

Clinical Perspectives on Targeting Therapies for Personalized Medicine.

Adv Protein Chem Struct Biol. 2016;102:79-114. doi: 10.1016/bs.apcsb.2015.11.003. Epub 2015 Dec 29.

Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Nat Rev Clin Oncol. 2011 Aug 23;8(10):587-96. doi: 10.1038/nrclinonc.2011.121.

Genomics in the post-GWAS era.

Semin Liver Dis. 2011 May;31(2):215-22. doi: 10.1055/s-0031-1276641. Epub 2011 May 2.

Overview of the development of personalized genomic medicine and surgery.

World J Surg. 2011 Aug;35(8):1693-9. doi: 10.1007/s00268-011-1056-0.

本文引用的文献

EGFR inhibitors embrace KRAS.

Nat Biotechnol. 2008 Aug;26(8):839-40. doi: 10.1038/nbt0808-839.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验